POLL: Which 2022 Psoriasis FDA Approval Were You Most Excited About?

Click here to answer this week's poll.

Which 2022 Psoriasis FDA Approval Were You Most Excited About?

Deucravacitinib
Tapinarof cream
Roflumilast cream
Spesolimab (generalized pustular psoriasis)
Related Videos
Related Content

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

March 22nd 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response

March 20th 2023

POLL: What Will Catch Your Eye In The AAD Exhibit Hall?

March 15th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

March 22nd 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response

March 20th 2023

POLL: What Will Catch Your Eye In The AAD Exhibit Hall?

March 15th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

March 22nd 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response

March 20th 2023

POLL: What Will Catch Your Eye In The AAD Exhibit Hall?

March 15th 2023
© 2023 MJH Life Sciences

All rights reserved.